Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review

Area of Science:

• Oncology
• Molecular Biology
• Clinical Pharmacology

Background:

• Pancreatic cancer is a leading cause of cancer-related mortality, with poor outcomes for advanced stages.
• Current treatment options for unresectable and metastatic pancreatic cancer are limited, necessitating novel therapeutic strategies.
• Molecularly targeted agents are under investigation to address specific signaling pathways implicated in pancreatic carcinogenesis.

Purpose of the Study:

• To systematically review and synthesize data from clinical trials on the efficacy and safety of molecularly targeted drugs in unresectable and metastatic pancreatic cancer.
• To evaluate the current landscape of targeted therapies in pancreatic cancer treatment.
• To identify promising agents and future directions for drug development.

Main Methods:

• Systematic literature review of clinical trials evaluating molecularly targeted drugs.
• Synthesis of efficacy and safety data from phase 3 trials.
• Analysis of approved agents and ongoing clinical development.

Main Results:

• Multiple molecularly targeted agents are in clinical development, targeting pathways such as angiogenesis, epidermal growth factor receptor, cell cycle, and proteasome.
• Only nine phase 3 trials have been completed, and erlotinib is the only FDA-approved agent for clinical use.
• Data synthesis indicates a need for more robust clinical trial evidence to establish the efficacy of targeted therapies.

Conclusions:

• Molecularly targeted agents represent a promising therapeutic avenue for pancreatic cancer, offering novel mechanisms of action.
• Further research and development of targeted therapies are crucial, given the current limitations in treating advanced pancreatic cancer.
• Continued investigation into the molecular mechanisms of pancreatic cancer will guide the development of more effective targeted treatments.